Literature DB >> 8220890

A facilitatory effect of anti-angiotensin drugs on vagal bradycardia in the pithed rat and guinea-pig.

M Rechtman1, H Majewski.   

Abstract

1. In pithed rats, preganglionic vagal nerve stimulation (at 5 Hz) elicited a bradycardia. This bradycardia was potentiated by the angiotensin converting enzyme inhibitor, captopril (1 mg kg-1, i.v.) by about 40%. Subsequent angiotensin II infusion (0.03 micrograms kg-1 min-1) reversed this effect. A similar facilitatory effect was also seen with the angiotensin receptor antagonist, losartan (10 mg kg-1, i.v.). These results suggest a tonic inhibitory effect of endogenous angiotensin II on vagal transmission. 2. The effect of captopril in potentiating vagal bradycardia appears to be at the level of vagal neurones, since the bradycardia elicited by the muscarinic agonist, methacholine was unaffected. 3. After the pithed rats were nephrectomized, captopril had no effect on vagally-induced bradycardia, suggesting that the formation of the endogenous angiotensin II responsible for the effect was dependent on renin release from the kidney. 4. When the sympathetic nerves of the pithed rat were electrically stimulated there was a tachycardia, and this was unaffected by captopril. However, when the sympathetic and vagus nerves were activated concurrently, the resulting tachycardia was inhibited by captopril. 5. In pithed guinea-pigs, captopril also potentiated the bradycardia caused by vagal nerve stimulation. This appears to be a tissue-selective effect since the bronchoconstriction due to the vagal stimulation was not affected by captopril. 6. These results suggest that endogenous angiotensin II can have a tonic inhibitory effect on cardiac vagal transmission. Disruption of this mechanism by anti-angiotensin drugs may attenuate the reflex tachycardia associated with the fall in blood pressure in anti-hypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8220890      PMCID: PMC2175998          DOI: 10.1111/j.1476-5381.1993.tb13807.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Effect of converting enzyme inhibition and angiotensin receptor blockade on the vasoconstriction mediated by alpha 1-and alpha 2-adrenoceptor stimulation in pithed normotensive rats.

Authors:  A de Jonge; J T Knape; J C van Meel; H O Kalkman; B Wilffert; M J Thoolen; P B Timmermanns; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-12       Impact factor: 3.000

2.  Angiotensin-converting enzyme inhibitors in the treatment of hypertension.

Authors:  C I Johnston; L Arnolda; M Hiwatari
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

3.  Peripheral inhibition of the parasympathetic nervous system by angiotensin.

Authors:  E K Potter
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1982

Review 4.  Neural regulation of the heart beat.

Authors:  M N Levy; P J Martin; S L Stuesse
Journal:  Annu Rev Physiol       Date:  1981       Impact factor: 19.318

Review 5.  Tissue renin-angiotensin systems and their modulation: the heart as a paradigm for new aspects of converting enzyme inhibition.

Authors:  K Lindpaintner; D Ganten
Journal:  Cardiology       Date:  1991       Impact factor: 1.869

6.  Captopril interferes with neurogenic vasoconstriction in the pithed rat by angiotensin-dependent mechanisms.

Authors:  R Hatton; D P Clough
Journal:  J Cardiovasc Pharmacol       Date:  1982 Jan-Feb       Impact factor: 3.105

7.  Angiotensin II does not inhibit vagally-induced bradycardia or gastric contractions in the anaesthetized ferret.

Authors:  P L Andrews; M B Dutia; P J Harris
Journal:  Br J Pharmacol       Date:  1984-08       Impact factor: 8.739

8.  Attenuation by captopril of pressor responses to peripheral sympathetic nerve stimulation in rats is abolished after bilateral nephrectomy and during mineralocorticoid hypertension.

Authors:  A L Boura; S C Hui; E J Ishac; M P Rechtman; W A Walters
Journal:  Clin Exp Pharmacol Physiol       Date:  1983 May-Jun       Impact factor: 2.557

9.  Attenuation by captopril of pressor responses to sympathetic stimuli: effects of procedures reducing activity of the renin-angiotensin system.

Authors:  A L Boura; M P Rechtman; W A Walters
Journal:  J Auton Pharmacol       Date:  1983-09

10.  Heart rate control in hypertensive patients treated by captopril.

Authors:  A Sturani; C Chiarini; E Degliesposti; A Santoro; A Zuccalà; P Zucchelli
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

View more
  5 in total

1.  Inhibitory effects of atropine and hexamethonium on the angiotensin II-induced contractions of rat anococcygeus smooth muscles.

Authors:  Márcio Augusto Fressatto de Godoy; Daniela Accorsi-Mendonça; Ana Maria de Oliveira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-16       Impact factor: 3.000

2.  Cardiac oxidative stress and dysfunction by fine concentrated ambient particles (CAPs) are mediated by angiotensin-II.

Authors:  Elisa Ghelfi; Gregory A Wellenius; Joy Lawrence; Emil Millet; Beatriz Gonzalez-Flecha
Journal:  Inhal Toxicol       Date:  2010-09       Impact factor: 2.724

3.  Direct positive chronotropic effects of angiotensin II and angiotensin III in pithed rats and in rat isolated atria.

Authors:  Q Li; J Zhang; M Pfaffendorf; P A van Zwieten
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Facilitation by procaterol, a beta-adrenoceptor agonist, of noradrenaline release in the pithed rat independently of angiotensin II formation.

Authors:  P Kotsonis; H Majewski
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 5.  Angiotensin II and the Cardiac Parasympathetic Nervous System in Hypertension.

Authors:  Julia Shanks; Rohit Ramchandra
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.